Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): Study protocol

BMC Pregnancy and Childbirth

Volumn 14, Issue 1, 2014, Pages

  Hund, Martin ^a   Allegranza, Deirdre ^a   Schoedl, Maria ^b   Dilba, Peter ^b   Verhagen Kamerbeek, Wilma ^a   Stepan, Holger ^c  

^a Roche Diagnostics Ltd   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Angiogenic factors; Antiangiogenic factors; Eclampsia; HELLP syndrome; Maternal outcome; Neonatal outcome; PlGF; Predictive markers; Preeclampsia; sFlt 1

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECLAMPSIA; FEMALE; FETUS OUTCOME; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MATERNAL SERUM; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PREECLAMPSIA; PREGNANCY OUTCOME; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; VALIDATION STUDY; ADOLESCENT; ALGORITHM; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; METHODOLOGY; MULTICENTER STUDY; PRE-ECLAMPSIA; PREDICTIVE VALUE; PREGNANCY; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; BIOMARKERS; DOUBLE-BLIND METHOD; ECLAMPSIA; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMANS; MEMBRANE PROTEINS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PROSPECTIVE STUDIES; RESEARCH DESIGN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84907922879     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-14-324     Document Type: Article

References (40)

1. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001, 20:IX-XIV. 10.3109/10641950109152635, 12044323.
2. Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C, de Swiet M, Fletcher G, Jokinen M, Murphy D, Nelson-Piercy C, Osgood V, Robson S, Shennan A, Tuffnell A, Twaddle S, Waugh J. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005, 330:576-580. 10.1136/bmj.330.7491.576, 554032, 15760998.
3. Lim K-H. Preeclampsia Medscape Reference Diseases and Conditions article, Updated 18 November 2013. [http://emedicine.medscape.com/article/1476919-overview#aw2aab6b3] (Accessed 11 December 2013).
4. Polsani S, Phipps E, Jim B. Emerging new biomarkers of preeclampsia. Adv Chronic Kidney Dis 2013, 20:271-279. 10.1053/j.ackd.2013.01.001, 23928393.
5. NICE clinical guideline 107 Hypertension in Pregnancy Last modified: January 2011, [http://www.nice.org.uk/nicemedia/live/13098/50418/50418.pdf] (Accessed 25 November 2013)., NICE clinical guideline 107.
6. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644. 10.1016/S0140-6736(10)60279-6, 20598363.
7. Scazzocchio E, Figueras F. Contemporary prediction of preeclampsia. Curr Opin Obstet Gynecol 2011, 23:65-71. 10.1097/GCO.0b013e328344579c, 21386680.
8. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, Roberts TE, Mol BW, van der Post JA, Leeflang MM, Barton PM, Hyde CJ, Gupta JK, Khan KS. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008, 12(6). [http://www.journalslibrary.nihr.ac.uk/__data/assets/pdf_file/0019/64621/FullReport-hta12060.pdf] (Accessed 6 December 2013).
9. Liu A, Wen SW, Bottomley J, Walker MC, Smith G. Utilization of health care services of pregnant women complicated by preeclampsia in Ontario. Hypertens Pregnancy 2009, 28:76-84. 10.1080/10641950802366252, 19165672.
10. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367:1066-1074. 10.1016/S0140-6736(06)68397-9, 16581405.
11. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology 2009, 24:147-158. 10.1152/physiol.00043.2008, 19509125.
12. Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, Hassan SS, Kim CJ, Chaiworapongsa T. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2012, 25:498-507. 10.3109/14767058.2011.591461, 3401571, 21867402.
13. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683. 10.1056/NEJMoa031884, 14764923.
14. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010, 202:161.e1-161.e11.
15. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012, 206:58.e1-58.e8.
16. Villa PM, Hämäläinen E, Mäki A, Räikkönen K, Pesonen AK, Taipale P, Kajantie E, Laivuori H. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth 2013, 13:110. 10.1186/1471-2393-13-110, 3661359, 23663420.
17. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014, 63:346-352. 10.1161/HYPERTENSIONAHA.113.01787, 24166751.
18. Schneider E, Gleixner A, Hänel R, Leyhe Y, Kleinschmidt C, Beck G, Steinberg M, Denk B, Gassner D. Technical performance of the first fully automated assays for human soluble fms-like tyrosine kinase 1 and human placental growth factor. Z Geburtshilfe Neonatol 2009, 213:A8. [https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0029-1216308]. (Accessed 25 November 2013).
19. Schiettecatte J, Russcher H, Anckaert E, Mees M, Leeser B, Tirelli AS, Fiedler GM, Luthe H, Denk B, Smitz J. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 2010, 43:768-770. 10.1016/j.clinbiochem.2010.02.010, 20206155.
20. ACOG Committee on Practice Bulletins-Obstetrics ACOG Practice Bulletin: diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002, 99:159-167. 10.1016/S0029-7844(01)01747-1, 16175681, ACOG Committee on Practice Bulletins-Obstetrics.
21. Magann EF, Martin NJ. Twelve steps to optimal management of HELLP syndrome. Clin Obstet Gynecol 1999, 42:532-550. 10.1097/00003081-199909000-00009, 10451769.
22. Von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003, 22:143-148. 10.1081/PRG-120021060, 12908998.
23. Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med 2007, 357:477-487. 10.1056/NEJMra050435, 17671256.
24. Stepan H. Intrauterine Wachstumsretardierung. Therapiehandbuch Gynäkologie und Geburtshilfe 2007, 45-50. Heidelberg: Springer Medizin, Wacker J, Bastert G, Sillem M, Beckmann MW.
25. Perinatal Institute for Maternal and Child Health Fetal Growth Customised Charts [http://www.perinatal.org.uk/FetalGrowth/fetalgrowth.aspx] (Accessed 08 Aug 2013).
26. Roche Diagnostics GmbH Elecsys/cobas PlGF immunoassay Package insert. 2013-08, V 5, [http://www.rochecanada.com/fmfiles/re7234008/package_inserts/05144671190_PLGF_EN_PI_V5.pdf] (Accessed 10 December 2013), Roche Diagnostics GmbH.
27. Roche Diagnostics GmbH Elecsys/cobas sFlt-1 immunoassay Package insert. 2013-08, V 5, [http://www.rochecanada.com/fmfiles/re7234008/package_inserts/sFlt-1-05109523190-English-CAN-V5.pdf] (Accessed 10 December 2013), Roche Diagnostics GmbH.
28. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction 2003, Oxford, UK: Oxford University Press.
29. Hund M, Allegranza D, Schoedl M, Verhagen-Kamerbeek WDJ. PROGNOSIS Study: Prediction of Short-Term Outcome in Pregnant Women With Suspected Preeclampsia Study Using the Angiogenic Biomarkers sFlt-1/PlGF 2013, Vienna, Austria: Presented at the 18th World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI).
30. Xu Q, Liang Y. Monte Carlo cross validation. Chemometr Intell Lab Syst 2001, 56:1-11.
31. Xu Q, Liang Y, Du Y. Monte Carlo cross validation for selecting a model and estimating the prediction error in multivariate calibration. J Chemom 2004, 18:112-120.
32. Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, Perschel FH, Karumanchi SA. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension 2012, 60:451-458. 10.1161/HYPERTENSIONAHA.112.195065, 3432569, 22753210.
33. Maynard SE, Crawford SL, Bathgate S, Yan J, Robidoux L, Moore M, Moore Simas TA. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am J Obstet Gynecol 2013, 209:53.e1-53.e9.
34. World Health Organization WHO Recommendations for Prevention and Treatment of Pre-eclampsia and Eclampsia 2011, Geneva, [http://whqlibdoc.who.int/publications/2011/9789241548335_eng.pdf] (Accessed 13 December 2013), World Health Organization.
35. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012, 125:911-919. 10.1161/CIRCULATIONAHA.111.054361, 3319742, 22261192.
36. Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, Simpson NA, North RA, . SCOPE consortium Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013, 120:1215-1223. 10.1111/1471-0528.12195, 23906160, SCOPE consortium.
37. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013, 128:2121-2131. 10.1161/CIRCULATIONAHA.113.003215, 24190934.
38. Chaiworapongsa T, Romero R, Korzeniewski SJ, Cortez JM, Pappas A, Tarca AL, Chaemsaithong P, Dong Z, Yeo L, Hassan SS. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med 2014, 27(2):132-144. 10.3109/14767058.2013.806905, 23687930.
39. DGGG Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen [http://www.awmf.org/leitlinien/detail/ll/015-018.html] (Accessed 14 January 2013), DGGG.
40. ACOG Task Force on Hypertension in Pregnancy Hypertension in Pregnancy 2013, American College of Obstetricians and Gynecologists, [http://www.acog.org/~/media/Task%20Force%20and%20Work%20Group%20Reports/HypertensioninPregnancy.pdf] (Accessed 11 December 2013), ACOG Task Force on Hypertension in Pregnancy.